131I-SPECT/CT usefulness in patients with Hashimoto’s thyroiditis (HT) coexistence with papillary thyroid carcinoma (PC) without risk factors at surgery followed in a long-term follow-up after thyroidectomy and radioiodine ablation
Abstract
Data di Pubblicazione:
2022
Citazione:
131I-SPECT/CT usefulness in patients with Hashimoto’s
thyroiditis (HT) coexistence with papillary thyroid
carcinoma (PC) without risk factors at surgery followed
in a long-term follow-up after thyroidectomy and
radioiodine ablation / Marongiu, A.; Nuvoli, S.; Solinas, P.; Rondini, M.; Papaleo, A.; Spanu, A.; Madeddu, G.. - In: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. - ISSN 1619-7070. - (2022).
Abstract:
Aim/Introduction: HT coexistence with PC has been reported, but
it remains controversial that autoimmune infammatory disease
may afect patient outcomes after thyroidectomy and radioiodine
ablation. We further evaluated this problem in HT/PC patient group
in long-term follow-up. Materials and Methods: Among a large HT/
PC patient group submitted to total thyroidectomy and radioiodine
ablation, 64 patients without risk factors at surgery, such as
extrathyroid tumor extension, multifocality, neck lymph node (LN),
or distant metastases were retrospectively enrolled. Tumor size was
≤10 in 42 cases and >10 in 22 cases. Forty-two patients were at very
low risk (VL) and 22 at low risk (L). We also evaluated 283 PC age/sex
control patients without HT and risk factors. All patients underwent
131I-whole-body scans (WBS) and SPECT/CT during follow-up after
185 MBq radioiodine diagnostic dose. In all cases, thyroglobulin
serum levels and AbTg were sequentially assayed. Results: During
follow-up, 20/64 HT/PC patients, 9 with microcarcinoma, developed
metastases (Group 1), while in 44/64 cases, 33 with microcarcinoma,
no metastases were ascertained (Group 2). In particular, in Group
1 patients, 9 VL and 11 L, WBS detected 9 metastatic neck LN
classifed as unclear in 9 patients, while SPECT/CT identifed 24
metastases characterizing the 9 unclear lesions and also 15 occult
lesions (14 neck and 1 mediastinal LN) in 11 cases. Thyroglobulin
was undetectable in 16 cases (12 with AbTg) and <2.5 ng/ml in
four cases (1 with AbTg). In Group 2 patients, no metastases were
ascertained at WBS and SPECT/CT. Among 283 control patients, 20
(7%), 10 VL and 10L, underwent metastases during follow-up. SPECT/
CT identifed 22 neck metastatic foci and 7 distant metastases (5
mediastinal, 1 lung, 1 spine), while WBS evidenced 5 neck and 3
distant metastases (2 mediastinal and 1 lung); however, except for
lung lesion, the other neoplastic foci were classifed as unclear at
WBS. Thyroglobulin was ≥2.5 ng/ml in 9 cases, undetectable in 11 (3
with AbTg). Conclusion: The HT/PC patients without risk factors at
surgery showed an adverse tumor course during follow-up in 31.2
% of cases, many of these with microcarcinoma. Unlike other studies
in the literature, the univariate analysis showed an increased risk of metastasis in patients with HT coexistence with PC, Odds ratio of
5.98 (95% CI 2.98-12.00) p<0.0001. Moreover, 131I-SPECT/CT proved
an accurate diagnostic tool to identify metastases with signifcantly
(p<0.0001) better performance than WBS also when thyroglobulin
was undetectable or very low.
it remains controversial that autoimmune infammatory disease
may afect patient outcomes after thyroidectomy and radioiodine
ablation. We further evaluated this problem in HT/PC patient group
in long-term follow-up. Materials and Methods: Among a large HT/
PC patient group submitted to total thyroidectomy and radioiodine
ablation, 64 patients without risk factors at surgery, such as
extrathyroid tumor extension, multifocality, neck lymph node (LN),
or distant metastases were retrospectively enrolled. Tumor size was
≤10 in 42 cases and >10 in 22 cases. Forty-two patients were at very
low risk (VL) and 22 at low risk (L). We also evaluated 283 PC age/sex
control patients without HT and risk factors. All patients underwent
131I-whole-body scans (WBS) and SPECT/CT during follow-up after
185 MBq radioiodine diagnostic dose. In all cases, thyroglobulin
serum levels and AbTg were sequentially assayed. Results: During
follow-up, 20/64 HT/PC patients, 9 with microcarcinoma, developed
metastases (Group 1), while in 44/64 cases, 33 with microcarcinoma,
no metastases were ascertained (Group 2). In particular, in Group
1 patients, 9 VL and 11 L, WBS detected 9 metastatic neck LN
classifed as unclear in 9 patients, while SPECT/CT identifed 24
metastases characterizing the 9 unclear lesions and also 15 occult
lesions (14 neck and 1 mediastinal LN) in 11 cases. Thyroglobulin
was undetectable in 16 cases (12 with AbTg) and <2.5 ng/ml in
four cases (1 with AbTg). In Group 2 patients, no metastases were
ascertained at WBS and SPECT/CT. Among 283 control patients, 20
(7%), 10 VL and 10L, underwent metastases during follow-up. SPECT/
CT identifed 22 neck metastatic foci and 7 distant metastases (5
mediastinal, 1 lung, 1 spine), while WBS evidenced 5 neck and 3
distant metastases (2 mediastinal and 1 lung); however, except for
lung lesion, the other neoplastic foci were classifed as unclear at
WBS. Thyroglobulin was ≥2.5 ng/ml in 9 cases, undetectable in 11 (3
with AbTg). Conclusion: The HT/PC patients without risk factors at
surgery showed an adverse tumor course during follow-up in 31.2
% of cases, many of these with microcarcinoma. Unlike other studies
in the literature, the univariate analysis showed an increased risk of metastasis in patients with HT coexistence with PC, Odds ratio of
5.98 (95% CI 2.98-12.00) p<0.0001. Moreover, 131I-SPECT/CT proved
an accurate diagnostic tool to identify metastases with signifcantly
(p<0.0001) better performance than WBS also when thyroglobulin
was undetectable or very low.
Tipologia CRIS:
1.5 Abstract in rivista
Elenco autori:
Marongiu, A.; Nuvoli, S.; Solinas, P.; Rondini, M.; Papaleo, A.; Spanu, A.; Madeddu, G.
Link alla scheda completa:
Pubblicato in: